antibody drug conjugates

AZ outlines AI-enabled TROP2 biomarker strategy for Daiichi ADC

AZ is using the biomarker in the phase 3 AVANZAR trial, which is evaluating Dato-DXd in combination with Imfinzi and chemo in first-line NSCLC.

Angus Liu Sep 8, 2024 12:22pm

Go sign green light

FDA allows BioNTech-MediLink ADC trial to resume at lower doses

Aug 19, 2024 8:45am

pay deal hand over cash licensing transaction money

ArriVent licenses ADC from $100M biobuck deal with Aarvik

Aug 15, 2024 8:58am

image of two race cars neck and neck

Exelixis drops ADC after deciding it's no match for Tivdak

Aug 7, 2024 5:22am

IPO initial public offering Wall Street

OS Therapies refiles $6M IPO to fund HER2 drug, preclinical ADCs

Aug 1, 2024 5:18am

Graphic of a brain inside of a lightbulb

AC Immune sees 'landmark' potential in brain-penetrating ADC

Jul 31, 2024 10:00am